Navigation Links
New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans

New Mexico Department of Veterans Services Partners with New Mexico Tech

and Biomoda, Inc.

ALBUQUERQUE, N.M., Feb. 14 /PRNewswire-FirstCall/ -- The New Mexico Institute of Mining and Technology (New Mexico Tech) and Biomoda, Inc. (OTC Bulletin Board: BMOD) (, have partnered with the New Mexico Department of Veterans Services (DVS) to conduct a $350,000 clinical study using proprietary testing technology for detection of early lung cancer in the state's veterans.

The $350,000 clinical program will be administered by New Mexico Tech, a science and engineering research university in Socorro. Biomoda, a biotech company focusing on very early cancer detection technology, through its Albuquerque office, will conduct the first year of the program using its patented non-invasive diagnostic technology for cost-efficient screening of early stage lung cancer in large populations. New Mexico Tech and the New Mexico Department of Veterans Services will oversee the clinical program.

"Early detection is critical to surviving lung cancer," said New Mexico Tech President Dr. Daniel H. Lopez. "Further enhancement and validation of these technologies will significantly impact the way we diagnose and treat lung cancer throughout the world. New Mexico Tech is excited to play a significant role on this project."

Biomoda's technology is based on a patented application that identifies cancerous or aberrant cells from samples of lung sputum. Cancerous cells glow red under fluorescent light and can be detected under a microscope. The technology is non-invasive and designed for cancer screening of large populations at a reasonable cost.

"By supporting this study, our state's public officials have illustrated the importance of caring for our veterans and providing the opportunity to be diagnosed, treated, and potentially cured of lung cancer by catching it in the early stages," said John Cousins, President of Biomoda.

Biomoda's team of experts will be dedicated to the year-long clinical study. The team includes representatives from TriCore Laboratories, Averion International, and Quintiles Consulting. The Black Veterans Association of New Mexico will assist with outreach to veterans.

With more than 160,000 people diagnosed every year, lung cancer represents 30 percent of all cancer deaths in the U.S. Veterans have a 25 percent higher risk exposure, incidence and lung cancer mortality rates than civilians.

For more information contact: Jamila Taylor

Calypso Communications


SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Post Your Comments:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - ... ... ... With ...
Breaking Biology News(10 mins):